Breaking: Promising Sonelokimab's HS Trial Data Propels MoonLake Immunotherapeutics
- June 26th, 2023
- 407 views
MoonLake Immunotherapeutics (Nasdaq: MLTX), a clinical-stage biotechnology company, announced positive results from its Phase 2 MIRA trial, evaluating the effectiveness and safety of the Nanobody sonelokimab, administered subcutaneously, in patients with moderate-to-severe hidradenitis suppurativa (HS).
Hidradenitis suppurativa is a painful skin condition characterized by lumps that form in areas where skin touches skin.
The trial successfully met its primary endpoint, with a higher proportion of patients treated with sonelokimab achieving Hidradenitis Suppurativa Clinical Response (HiSCR) 75 compared to those on placebo at week 12.
The results showed that sonelokimab exhibits strong clinical activity compared to other therapies evaluated in similar trials.
At present, $MLTX is trading at $47.59, representing a significant increase of $21.71 (+83.89%).
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
FTC Takes Action to Prevent Anticompetitive Arrangement in Beretta, Ruger Deal
September 16th, 2026Why Opponent Preparation Matters for Post-Graduate Athletes
September 16th, 2026The Work Behind the Game: How Football Teams Prepare to Compete
September 15th, 2026NJCP Operates on a Prep Model Built Around a Full Season
September 14th, 2026Earnings Preview: High Tide, Kestra Medical, and RF Industries in Focus
September 12th, 2026
Member Login